NYSE:NVS

OLON Continues Strategic Collaboration With Novartis, Supporting the Expansion of the Africa Sickle Cell Disease Program to Kenya, Uganda and Tanzania

Press Release

October 1, 2020 /3BL Media/ - OLON announced it will continue its collaboration with Novartis to support the Africa Sickle Cell Disease program as it expands to Kenya, Uganda and Tanzania.  Initially launched in 2019 by Novartis and its partners in Ghana, the Africa Sickle Cell Disease program intends to improve the lives of people with sickle cell disease and accelerate access to treatment and related laboratory tests.

Life Science Companies and the Bill & Melinda Gates Foundation: Commitments to Expanded Global Access for COVID-19 Diagnostics, Therapeutics, and Vaccines

Press Release

September 30, 2020 /3BL Media/ - COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organizations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pandemic worldwide.

Novartis US Foundation Commits $25M to Improve Health Equity by Reducing Health Disparities in the US

Summary: 
  • Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice
  • Commitment to include partnerships and support to address the underrepresentation of minorities, including African American/Black and Hispanic communities, in clinical trials
  • Reinforces US Foundation focus on improving health by strengthening health systems, eliminating barriers to care and addressing social determinants of health
Press Release
  • Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice
  • Commitment to include partnerships and support to address the underrepresentation of minorities, including African American/Black and Hispanic communities, in clinical trials
  • Reinforces US Foundation focus on improving health by strengthening health systems, eliminating barriers to care and addressing social determinants of health

Novartis Reinforces Commitment to Patient Access, Pricing a EUR 1.85 Billion Sustainability-linked Bond

Summary: 
  • First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations
  • SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%
Press Release
  • First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations
  • SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%

Lower-Income Countries Could Soon Leapfrog High-Income Countries With AI-Enabled Health Technologies, Novartis Foundation and Microsoft Backed Report Says

Summary: 
  • Investment in data and AI will be a key tool driving health system improvements during and after the COVID-19 pandemic
  • Lower income countries could be the fastest adopters due to lack of legacy systems, but have the most to lose if governments don’t invest now
  • The report uses current AI best practices to draw a roadmap that can help all countries advance towards AI maturity in health
Press Release
  • Investment in data and AI will be a key tool driving health system improvements during and after the COVID-19 pandemic
  • Lower income countries could be the fastest adopters due to lack of legacy systems, but have the most to lose if governments don’t invest now
  • The report uses current AI best practices to draw a roadmap that can help all countries advance towards AI maturity in health

New Collaboration Between Novartis and Africa Medical Supplies Platform to Facilitate Supply of COVID-19 Related Medicines

Summary: 
  • The collaboration aims to help alleviate supply and logistical constraints in the African Union member states
     
  • Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division will be sold at zero-profit to governments through Africa Medical Supplies Platform (AMSP) to 55 African and 15 Caricom eligible countries
     
  • The African Union through the AMSP has integrated vetted medical suppliers to ensure rapid access to affordable COVID-19 related supplies
Press Release
  • The collaboration aims to help alleviate supply and logistical constraints in the African Union member states
     
  • Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division will be sold at zero-profit to governments through Africa Medical Supplies Platform (AMSP) to 55 African and 15 Caricom eligible countries
     
  • The African Union through the AMSP has integrated vetted medical suppliers to ensure rapid access to affordable COVID-19 related supplies

Novartis Announces Ambitious ESG Targets to Increase Access to Medicines and Achieve Full Carbon Neutrality

Summary: 
  • 2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across these initiatives
  • Enhanced target for full carbon neutrality across all company operations and entire supply chain by 2030
  • New collaboration with the African Union initiated Africa Medical Supplies Platform to aid supply of Novartis COVID-19 Pandemic Response Portfolio
  • Company completed enrollment in the CAN-COVID Phase III clinical trial with expected readout in Q4 2020
Press Release
  • 2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across these initiatives
  • Enhanced target for full carbon neutrality across all company operations and entire supply chain by 2030
  • New collaboration with the African Union initiated Africa Medical Supplies Platform to aid supply of Novartis COVID-19 Pandemic Response Portfolio
  • Company completed enrollment in the CAN-COVID Phase III clinical trial with expected readout in Q4 2020

Novartis Launches First-of-Its-Kind Not-for-Profit Portfolio of Medicines for Symptomatic Treatment of COVID-19

Press Release
  • Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms
  • Portfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available
  • Early access to treatment for managing  COVID-19 symptoms is critical to preventing healthcare system overload

New Agreements to Expand Access to 20 Lifesaving Cancer Medicines for Countries in Sub-Saharan Africa and Asia

Cancer Access Partnership is expected to result in a 59 percent savings on procured cancer medicines
Press Release

June 29, 2020 /3BL Media/ - The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements.

Pages

Subscribe to NYSE:NVS